Development of recombinant subunit vaccine targeting InvH protein of Salmonella Typhimurium and evaluation of its immunoprotective efficacy against salmonellosis

Salmonella Typhimurium is the most prevalent non-host specific Salmonella serovars and a major concern for both human and animal health systems worldwide contributing to significant economic loss. Type 3 secretion system (T3SS) of Salmonella plays an important role in bacterial adherence and entry i...

Full description

Saved in:
Bibliographic Details
Published inBrazilian journal of microbiology Vol. 54; no. 4; pp. 3257 - 3264
Main Authors Choudhury, Mridusmita, Borah, Probodh, Sarma, Hridip Kumar, Deka, Dipak, Dutta, Rupam, Hazarika, Girin, Deka, Naba Kumar
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.12.2023
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Salmonella Typhimurium is the most prevalent non-host specific Salmonella serovars and a major concern for both human and animal health systems worldwide contributing to significant economic loss. Type 3 secretion system (T3SS) of Salmonella plays an important role in bacterial adherence and entry into the host epithelial cells. The product of invH gene of Salmonella is an important component of the needle complex of the type 3 secretion system. Hence, the present study was undertaken to clone and express the 15 kDa InvH surface protein of Salmonella Typhimurium in an E. coli host and to evaluate its immune potency in mice. The purified recombinant InvH (r-InvH) protein provoked a significant ( p  < 0.01) rise in IgG in the inoculated mice. The immunized mice were completely (100%) protected against the challenge dose of 107.5 LD50, while protection against challenge with the same dose of heterologous serovars was 90%. The bacterin-vaccinated group showed homologous protection of 60% against all three serovars. Findings in this study suggest the potential of the r-InvH protein of S . Typhimurium as an effective vaccine candidate against Salmonella infections.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Responsible Editor: Roxane M Piazza
ISSN:1517-8382
1678-4405
1678-4405
DOI:10.1007/s42770-023-01136-6